STOCK TITAN

Akero Therapeutics Stock Price, News & Analysis

AKRO Nasdaq

Welcome to our dedicated page for Akero Therapeutics news (Ticker: AKRO), a resource for investors and traders seeking the latest updates and insights on Akero Therapeutics stock.

Akero Therapeutics (NASDAQ: AKRO) is a clinical-stage biotechnology company pioneering FGF21-based therapies for metabolic diseases including NASH and MASH. This page provides investors and researchers with timely updates on clinical developments, regulatory milestones, and corporate announcements directly from the company.

Access authoritative information on Akero's lead candidate efruxifermin (EFX), including Phase 2b/3 trial progress, peer-reviewed research, and strategic partnerships. Our curated news collection covers essential updates, scientific presentations, and financial reports while maintaining strict compliance with financial disclosure standards.

Key content includes trial result analyses, FDA communications, patent developments, and executive commentary. Bookmark this page for streamlined tracking of Akero's progress in addressing liver fibrosis and metabolic dysfunction through innovative Fc-FGF21 fusion protein therapy.

Rhea-AI Summary

Akero Therapeutics (Nasdaq: AKRO) has announced the pricing of an upsized public offering, consisting of 5,333,420 shares of common stock at $48.00 per share and pre-funded warrants to purchase 1,958,247 shares at $47.9999 per warrant. The pre-funded warrants have an exercise price of $0.0001 per share.

The company expects to raise approximately $350.0 million in gross proceeds before deducting underwriting costs and expenses. Akero has granted underwriters a 30-day option to purchase up to an additional 1,093,750 shares. The offering is expected to close around January 30, 2025.

J.P. Morgan, Morgan Stanley, and Jefferies are serving as joint book-running managers, with UBS Investment Bank acting as co-manager for the offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.92%
Tags
-
Rhea-AI Summary

Akero Therapeutics (NASDAQ: AKRO), a clinical-stage company focused on metabolic disease treatments, has announced a proposed public offering of $300.0 million of common stock shares. The company plans to grant underwriters a 30-day option to purchase up to an additional $45.0 million of shares at the public offering price, less underwriting discounts and commissions.

The offering will be managed by J.P. Morgan, Morgan Stanley, and Jefferies as joint book-running managers. The securities will be offered through an automatically effective shelf registration statement previously filed with the SEC. The completion of the offering is subject to market and other conditions, with no guarantee of completion or final terms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.46%
Tags
-
Rhea-AI Summary

Akero Therapeutics (NASDAQ: AKRO) has announced significant topline results from its Phase 2b SYMMETRY study evaluating efruxifermin (EFX) in patients with compensated cirrhosis due to MASH. The study demonstrated statistically significant reversal of cirrhosis at Week 96:

- Among patients with baseline and week 96 biopsies, 39% of the 50mg EFX group showed ≥1 stage improvement in fibrosis with no worsening of MASH, compared to 15% for placebo (24% effect size).

- In the Intent to Treat analysis, 29% of the 50mg EFX group demonstrated improvement, compared to 12% for placebo (17% effect size).

The study revealed stronger results in patients not taking GLP-1 at baseline, with 45% showing cirrhosis reversal in the 50mg group versus 17% for placebo. EFX was generally well-tolerated, with most adverse events being grade 1 or 2 gastrointestinal issues.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
97.52%
Tags
Rhea-AI Summary

Akero Therapeutics (NASDAQ: AKRO) has announced an upcoming investor webcast scheduled for Monday, January 27, 2025, at 8:00 a.m. ET. The company will present preliminary topline week 96 results from its SYMMETRY Phase 2b study, which evaluates efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to metabolic dysfunction-associated steatohepatitis (MASH).

The study is designed as a double-blind, placebo-controlled trial. The presentation will include a webcast with slides, available on the Events & Presentations page of Akero's website, with recording and presentation materials to be made available immediately after the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
97.52%
Tags
conferences clinical trial
-
Rhea-AI Summary

Akero Therapeutics has completed enrollment of the double-blind portion of its Phase 3 SYNCHRONY Real-World study, focusing on the safety and tolerability of Efruxifermin (EFX) in patients with MASH or MASLD. A total of 601 patients have been enrolled since the study's initiation in November 2023. The study assesses the safety and tolerability of EFX, administered once-weekly in 50mg doses, over 52 weeks.

The SYNCHRONY Real-World study is a randomized, double-blind, placebo-controlled trial, with primary endpoints on safety and tolerability. Secondary endpoints include changes in non-invasive markers of liver fibrosis and injury, as well as lipoproteins, glycemic control, and body weight. An open-label cohort includes patients previously assigned to placebo in Phase 2b studies. Data from this study are expected in the first half of 2026.

Akero's Chief Development Officer, Kitty Yale, noted the rapid enrollment as indicative of the significant need for MASH treatments and optimism surrounding EFX's potential. Previous Phase 2 studies have shown improvements in liver histology and non-invasive liver health markers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.9%
Tags
-
Rhea-AI Summary

Akero Therapeutics (Nasdaq: AKRO), a clinical-stage company focused on developing treatments for serious metabolic diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management will deliver a presentation on Tuesday, January 14, 2025, at 11:15 a.m. Pacific Time.

Interested parties can access a live webcast of the presentation through the investor relations section of Akero's website at www.akerotx.com. An archived version of the presentation will also be made available on the company's website following the live broadcast.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.73%
Tags
conferences
Rhea-AI Summary

Akero Therapeutics (Nasdaq: AKRO) has announced its participation in the 7th Annual Evercore ISI HealthCONx Conference. The company's management will engage in a fireside chat on Tuesday, December 3, 2024, at 9:10 a.m. ET. The presentation will be accessible through a live webcast via the investor relations section of Akero's website at www.akerotx.com, with an archived replay available afterward. Akero is a clinical-stage company focused on developing treatments for serious metabolic diseases with high unmet medical needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
conferences
-
Rhea-AI Summary

Akero Therapeutics presented new analyses of its Phase 2b HARMONY study for efruxifermin (EFX) in treating metabolic dysfunction-associated steatohepatitis (MASH). Over 40% of participants treated with EFX 50mg for 96 weeks showed regression of liver fibrosis across three measures, compared to 0% for placebo. 30% of participants receiving EFX 50mg achieved almost complete MASH disease reversal. The study demonstrated consistent improvements in liver health markers, with AI-based digital pathology confirming conventional histopathology assessments. The 50mg dose showed superior results compared to the 28mg dose, with significant reductions in fibrosis in both perisinusoidal and periportal zones of the liver.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.61%
Tags
-
Rhea-AI Summary

Akero Therapeutics (Nasdaq: AKRO) has announced its upcoming participation in the Jefferies London Healthcare Conference. The company's management will engage in a fireside chat on Tuesday, November 19, 2024, at 12:00 p.m. GMT. Akero, which focuses on developing treatments for serious metabolic diseases, will make the presentation available via live webcast through their investor relations website. An archived replay will be accessible on www.akerotx.com following the live event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.91%
Tags
conferences
Rhea-AI Summary

Akero Therapeutics (AKRO) reports Q3 2024 financial results and progress in its Phase 3 SYNCHRONY program for efruxifermin (EFX) in MASH treatment. The company reached a milestone with first patient dosing in SYNCHRONY Outcomes study for compensated cirrhosis. Cash position stands at $787.1 million, expected to fund operations into H2 2027. Q3 operating expenses increased to $81.7 million from $46.6 million year-over-year, mainly due to expanded clinical trials. Phase 3 SYNCHRONY Real-World and Histology studies are progressing, with results expected in 2026 and H1 2027, respectively. Phase 2b SYMMETRY study week 96 results anticipated in February 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags

FAQ

What is the current stock price of Akero Therapeutics (AKRO)?

The current stock price of Akero Therapeutics (AKRO) is $51.57 as of July 11, 2025.

What is the market cap of Akero Therapeutics (AKRO)?

The market cap of Akero Therapeutics (AKRO) is approximately 4.1B.
Akero Therapeutics

Nasdaq:AKRO

AKRO Rankings

AKRO Stock Data

4.13B
72.10M
2.34%
93.59%
6.35%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO